ZYBT Shariah Compliance
Screening Methodology: AAOIFI
HALAL
Last Updated: February 05, 2026
Report Source: 2025 2nd Quarter Report
Zhengye Biotechnology Holding Ltd. Stock Analysis ZYBT
Zhengye Biotechnology Holding Ltd. engages in the manufacture and sale of veterinary vaccines. The company is headquartered in Jilin, Jilin and currently employs 277 full-time employees. The company went IPO on 2025-01-07. The firm markets a diverse range of vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs. The firm owns about 44 veterinary vaccines in its product portfolio, which cover veterinary vaccines for livestock, including monovalent vaccine, polyvalent vaccine, combined vaccine and combined and polyvalent vaccine. The firm also engages in vaccines for treating livestock. The firm mainly conducts its business in the domestic market. The firm mainly conducts its business in the domestic and overseas market.
Read More Zhengye Biotechnology Holding Ltd (ZYBT) Chart
Key Statistics of Zhengye Biotechnology Holding Ltd (ZYBT)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$0.93Volume
4401.00P/E Ratio (TTM)
-52 Week Range
Market Cap
53.55MAvg. Volume
69.94KDividend Yield
-Financial Metrics & Statements of Zhengye Biotechnology Holding Ltd (ZYBT)
FAQ's for Zhengye Biotechnology Holding Ltd (ZYBT)
- According to Musaffa’s Shariah screening methodology, Zhengye Biotechnology Holding Ltd (ZYBT) is currently classified as HALAL as of February 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.